Pharma BD Deal Intelligence

Hansoh Pharmaceutical Group Co. Ltd. / AilsynBio

2026 · Licensing/Option · Complete

A wholly owned subsidiary of Hansoh Pharmaceutical Group entered a collaboration development agreement with AilsynBio to apply AilsynBio's AI platform to the discovery of novel oral cyclic peptide drug candidates. Hansoh may select targets, acquire the intellectual property rights for the corresponding programs and lead subsequent development. AilsynBio is eligible for aggregate payments of up to RMB 317 million plus single-digit royalties on potential net sales of products developed under the programs.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal.

Key facts

Related deals

See the full interactive analysis, sources & comparables →